PLCO试验中前列腺癌诊断后的其他原因及全因死亡率
基于PLCO癌症筛查试验队列,纳入1994-2014年诊断的10,859例前列腺癌患者,其中9,248例(85.2%)有已知危险度分层。中位随访10.8年,3,318例死亡中81%为其他原因死亡;与低危组相比,中危、高危和晚期疾病的其他原因死亡HR在模型II中分别为1.13、1.35和1.63。
要点
- 前列腺癌患者多数死于其他原因,而非前列腺癌本身。
- 危险度越高,其他原因死亡风险越高,低危组最低。
- 控制生活方式和合并症后,其他原因死亡风险梯度仍存在。
核心结论
- 低危前列腺癌患者其他原因生存优于高危和晚期患者,即使控制生活方式特征和合并症后仍如此。
研究设计与样本
- 基于PLCO癌症筛查试验队列,选取1994-2014年诊断的前列腺癌患者,共10,859例,其中9,248例(85.2%)有已知危险度分层,平均年龄70.4±6.2岁。
主要发现
- 中位随访10.8年(IQR 6.8-15.0),3,318例死亡中81%为其他原因死亡。
- 模型II中,与低危组相比,中危、高危和晚期疾病的其他原因死亡HR分别为1.13(95%CI 1.04-1.23)、1.35(95%CI 1.21-1.50)和1.63(95%CI 1.35-1.97)。
- 模型III中,除晚期疾病HR降至1.35外,其余HR与模型II相似。
临床怎么用
- 对前列腺癌患者,尤其是中高危和晚期患者,应关注其他原因死亡风险,加强合并症管理和生活方式干预。
局限性
- 需进一步研究确定导致其他原因死亡率升高的因素,以帮助降低风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Men with prostate cancer have high cause-specific survival, and most deaths are from other causes. This study aimed to investigate other and all-cause mortality in a large cancer screening cohort. MATERIALS AND METHODS: From the PLCO (Prostate, Lung, Colorectal and Ovarian) Cancer Screening Trial cohort, we selected men diagnosed with prostate cancer from 1994-2014. We examined other and all-cause survival by prostate cancer risk level, defined as the D'Amico categories for localized disease (low, intermediate and high risk) plus nonlocalized disease. We developed 3 Cox proportional hazards models to assess the relationship between risk level and survival. Model I controlled for age, race, study arm and diagnosis year. Model II additionally controlled for other demographic and medical history factors. Model III additionally controlled for initial treatment. RESULTS: Of 76,672 men in PLCO and 10,859 prostate cancer cases, 9,248 (85.2%) had known prostate cancer risk level (mean±SD age 70.4±6.2 years). Median followup time from diagnosis was 10.8 years (IQR 6.8-15.0). Of 3,318 deaths 81% were from other causes. Compared to the low risk group, other-cause mortality HRs were 1.13 (95% CI 1.04-1.23), 1.35 (95% CI 1.21-1.50) and 1.63 (95% CI 1.35-1.97) for intermediate risk, high risk and advanced disease, respectively, in model II. Model III HRs were similar to model II except for advanced disease, where the HR decreased to 1.35. CONCLUSIONS: Other-cause survival was greater in lower vs higher risk disease, even after controlling for lifestyle characteristics and comorbidities. Further research is needed to identify factors contributing to this higher other-cause mortality to help mitigate the risk.
引用
- Pierre-Victor D, Pinsky PF, Miller E, et al. Other and All-Cause Mortality among Men Diagnosed with Prostate Cancer in the PLCO Trial. J Urol. 2020. PMID: 33350321. doi:10.1097/JU.0000000000001531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。